Warmuth Markus 4

What Happened

• Markus Warmuth, President & CEO and a director of Monte Rosa Therapeutics (GLUE), sold 5,467 shares on 2026-05-01. The weighted-average price was $18.92, producing proceeds of about $103,447. This was a sale (not a purchase), which is often routine insider liquidity rather than an investment signal.

Key Details

• Transaction date: 2026-05-01; filing date: 2026-05-05.
• Reported weighted-average price: $18.92; total proceeds: ~$103,447.
• Price range (per filing): sales occurred at prices between $18.67 and $19.38; the reporting person can provide a breakdown by price on request (footnote).
• Shares owned after the transaction: not disclosed in the provided excerpt of the filing.
• Footnotes: F1 — transaction effected under a Rule 10b5-1 trading plan adopted May 14, 2025. F2 — weighted-average price with per-trade price range disclosed.
• Filing timeliness: filing date and report period are shown; no late-filing flag was provided in the excerpt.

Context

• The sale was executed under a pre-established Rule 10b5-1 plan, which typically sets up scheduled trades and can explain routine insider sales.
• Sales do not necessarily indicate negative insider sentiment; purchases tend to be more informative about confidence in the company.